Diabetes mellitus (D.M) is a disease with a high and increasingprevalence. Insulin-producing cells (IPCs) generated frommesenchymal stem cells (MSCs) have shown immense potential fortherapy. This study aimed to compare the differentiation potential of 2kinds of MSCs obtained from human bone marrow (BM), andumbilical cord blood (UCB) into IPCs. In addition, their therapeuticefficiency to control streptozotocin (STZ) – induced diabetic rats wasinvestigated. MSCs were isolated from human BM and UCB,expanded and differentiated to IPCs. The Cells were evaluated byflow cytometry analysis for MSCs markers, RT-PCR for insulin geneexpression and ELISA detection of C-peptide release. IPCS weretransplanted into the liver of diabetic rats and then evaluated byweekly measurement of the fasting blood glucose (FBG) levels, anddetection of in vivo release of C-peptide. This study demonstrated thatFBG levels were reduced in diabetic rats transplanted with IPCs, butin rats transplanted with UCB-derived cells were significantly lowerthan in those transplanted with BM-derived cells. The amount of Cpeptidereleased from transplanted IPCs derived from BM-MSCs andUCB-MSCs was non-significantly different. The results indicate thatUCB- MSCs and BM-MSCs are promising stem cell sources for IPCsthat help in the development of a new strategy for treatment of D.M.
No takes yet. Share an insight, caveat, or question.
El-Nablaway et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: